Bristol's Opdivo Delivers, But CheckMate 227 Uncertainties Cloud Quarter

The use of the emerging tumor mutation burden biomarker and its relevance to the outcome of the CheckMate 227 study of Opdivo/Yervoy in first-line lung cancer was a hot topic during Bristol's Q3 earnings call, but questions remain.

business card

Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo continues to deliver impressive sales despite increased competition, but uncertainties about the all-important CheckMate 227 study of combination use with Yervoy in first-line non-small cell lung cancer, including the relevance of tumor mutation burden as an emerging immuno-oncology biomarker, cast a bit of a cloud on the third quarter.

Bristol reported sales of about $1.3bn for Opdivo (nivolumab) for the third quarter, up 38% from the same period in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.